Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ancillary one-day blood sampling safety study in psoriasis subjects previously treated with Raptiva
NL-OMON32149Phase 4Withdrawn
- Sponsor
- Serono
- Start
- Apr 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of efalizumab in psoriasis (3 arms), sponsored by Serono. Primary endpoints: Binding anti-efalizumab antibody prevalence in autoimmune disorder subgroup and Binding anti-efalizumab antibody prevalence in severe thrombocytopenia subgroup. Planned start Apr 2008; status: withdrawn.
02
Drugs
efalizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON32149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32149.